Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed the day trading at $6.09 up 16.44% from the previous closing price of $5.23. In other words, the price has increased by $16.44 from its previous closing price. On the day, 93.5 million shares were traded. RXRX stock price reached its highest trading level at $6.3 during the session, while it also had its lowest trading level at $5.19.
Ratios:
For a better understanding of RXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.58. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 25 ’25 when Gibson Christopher sold 100,000 shares for $4.76 per share. The transaction valued at 476,000 led to the insider holds 954,229 shares of the business.
Gibson Christopher bought 100,000 shares of RXRX for $476,000 on Sep 25 ’25. On Sep 10 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 100,000 shares for $4.71 each. As a result, the insider received 471,000 and left with 974,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2658580736 and an Enterprise Value of 2210064384. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.98 while its Price-to-Book (P/B) ratio in mrq is 2.87. Its current Enterprise Value per Revenue stands at 34.214 whereas that against EBITDA is -3.769.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.91, which has changed by -0.014563084 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 19.44%, while the 200-Day Moving Average is calculated to be 4.46%.
Shares Statistics:
Over the past 3-months, RXRX traded about 26.82M shares per day on average, while over the past 10 days, RXRX traded about 47040450 shares per day. A total of 425.48M shares are outstanding, with a floating share count of 332.98M. Insiders hold about 23.39% of the company’s shares, while institutions hold 53.78% stake in the company. Shares short for RXRX as of 1757894400 were 132044177 with a Short Ratio of 4.92, compared to 1755216000 on 122223405. Therefore, it implies a Short% of Shares Outstanding of 132044177 and a Short% of Float of 32.45.
Earnings Estimates
. The current market rating for Recursion Pharmaceuticals Inc (RXRX) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.29 and -$1.8 for the fiscal current year, implying an average EPS of -$1.58. EPS for the following year is -$1.28, with 9.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
5 analysts predict $19.36M in revenue for. The current quarter. It ranges from a high estimate of $23.9M to a low estimate of $16M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $26.08MFor the next quarter, 5 analysts are estimating revenue of $17.7M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $16M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $95.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $69.68M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $97.31M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
